Bonek, K.; Roszkowski, L.; Massalska, M.; Maslinski, W.; Ciechomska, M.
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021, 10, 323.
https://doi.org/10.3390/cells10020323
AMA Style
Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M.
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells. 2021; 10(2):323.
https://doi.org/10.3390/cells10020323
Chicago/Turabian Style
Bonek, Krzysztof, Leszek Roszkowski, Magdalena Massalska, Wlodzimierz Maslinski, and Marzena Ciechomska.
2021. "Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment" Cells 10, no. 2: 323.
https://doi.org/10.3390/cells10020323
APA Style
Bonek, K., Roszkowski, L., Massalska, M., Maslinski, W., & Ciechomska, M.
(2021). Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells, 10(2), 323.
https://doi.org/10.3390/cells10020323